AU4589297A - Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase - Google Patents

Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase

Info

Publication number
AU4589297A
AU4589297A AU45892/97A AU4589297A AU4589297A AU 4589297 A AU4589297 A AU 4589297A AU 45892/97 A AU45892/97 A AU 45892/97A AU 4589297 A AU4589297 A AU 4589297A AU 4589297 A AU4589297 A AU 4589297A
Authority
AU
Australia
Prior art keywords
secretase
beta
forming enzyme
direct inhibitors
identify direct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45892/97A
Inventor
Barbara Cordell
Jeffrey N Higaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Publication of AU4589297A publication Critical patent/AU4589297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU45892/97A 1996-10-07 1997-09-19 Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase Abandoned AU4589297A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72652496A 1996-10-07 1996-10-07
US08726524 1996-10-07
PCT/US1997/016988 WO1998015828A1 (en) 1996-10-07 1997-09-19 Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase

Publications (1)

Publication Number Publication Date
AU4589297A true AU4589297A (en) 1998-05-05

Family

ID=24918956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45892/97A Abandoned AU4589297A (en) 1996-10-07 1997-09-19 Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase

Country Status (2)

Country Link
AU (1) AU4589297A (en)
WO (1) WO1998015828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US6331408B1 (en) * 1998-11-12 2001-12-18 Robert Zaczek Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
DE19856261C1 (en) 1998-12-07 2000-03-30 Hoechst Marion Roussel De Gmbh Detection of gamma-secretase by detection of A-beta peptide useful for determining gamma-secretase activity and for identifying inhibitors
US6545127B1 (en) 1999-06-28 2003-04-08 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
DE19941039A1 (en) * 1999-08-28 2001-03-01 Boehringer Ingelheim Pharma gamma-secretase in vitro test system
GB9924957D0 (en) * 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
GB9925136D0 (en) * 1999-10-22 1999-12-22 Smithkline Beecham Plc Novel treatment
DE10000161A1 (en) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Determining test substances that inhibit protease, involves incubating cells expressing fusion protein having substrate with cleavage site for protease and reporter, measuring cleaved reporter and comparing with standard
WO2001053255A1 (en) * 2000-01-24 2001-07-26 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
US6753410B2 (en) 2000-03-02 2004-06-22 Merck & Co., Inc. Investigational compounds
AU4971701A (en) 2000-04-03 2001-10-15 Bristol Myers Squibb Co Isolation of functionally active gamma-secretase protein complex and methods fordetection of activity and inhibitors thereof
US6579689B2 (en) 2000-05-11 2003-06-17 Scios Inc. Modulation of γ-secretase activity
WO2001092235A1 (en) 2000-06-01 2001-12-06 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
DE10032709A1 (en) * 2000-07-07 2002-01-24 Boehringer Ingelheim Pharma Aspartyl protease
US6392787B1 (en) * 2000-09-01 2002-05-21 Agere Systems Guardian Corp. Process for fabricating article comprising photonic band gap material
EP1392340A4 (en) * 2001-03-30 2006-04-26 Buck Inst Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
DE10131899A1 (en) * 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In Vitro Screening Assay for Gamma Secretase
AU2002359301B2 (en) 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
GB0202276D0 (en) * 2002-01-31 2002-03-20 Eisai London Res Lab Ltd Assays
EP1481987A1 (en) * 2003-05-26 2004-12-01 Aventis Pharma Deutschland GmbH Method for screening inhibitors of the gamma-secretase
WO2005031363A1 (en) * 2003-09-24 2005-04-07 University Of Chicago Membrane preparation from pichia pastoris to assay ϝ-secretase activity
CN1925869A (en) * 2004-01-29 2007-03-07 塞尔卓姆股份公司 Treatment of neurodegenerative diseases by the use of GPR49
JP2007525491A (en) * 2004-01-29 2007-09-06 セルゾーム・アクチェンゲゼルシャフト Treatment of neurodegenerative diseases by use of GPR49
US7544855B2 (en) 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679675B2 (en) * 1992-05-11 1997-07-10 Bayer Corporation Methods for detecting beta amyloid precursor protein processing enzymes
EP0580161A1 (en) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Prophylactic and therapeutic treatment of Alzheimer's disease
JPH09178743A (en) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd Determinationof soluble app

Also Published As

Publication number Publication date
WO1998015828A1 (en) 1998-04-16

Similar Documents

Publication Publication Date Title
AU4589297A (en) Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
HUT76622A (en) Inhibitors of interlaukin-1beta converting enzyme
AU2644697A (en) Isolation of enzymes
AU7412196A (en) 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of beta-amyloid protein production
AU1536799A (en) Bishydroxyureas as inhibitors of the 5-lipoxygenase
AU2713297A (en) Process for stereoselective preparation of trans-azetidinones
AU4149197A (en) Method for production of magnesium
AU2277597A (en) New inhibitors of sh2-mediated processes
ZA9610798B (en) Inhibitors of interleuken-1beta converting enzyme
AU7318396A (en) Methods of preserving microorganisms
AUPO776697A0 (en) Method of increasing the iron content of plant cells
AU3256097A (en) Enzymatic esterification process
AU5702698A (en) Polyprolyl inhibitors of cyclophilin
AU1502299A (en) Method to identify specific inhibitors of imp dehydrogenase
AU1220599A (en) Method for the production and use of dendritic cells
AU730990C (en) Method of improving shotcrete technology
AUPO235996A0 (en) Method of cell culture
AU2707897A (en) Direct electrochemistry of enzymes
AU5556298A (en) Purification of fermented clavulanic acid
AU3355297A (en) Specific inhibitors of dna methyltransferase enzyme
AU2620895A (en) Microorganism-containing composition and method for the production of xylitol
AU1915697A (en) New efficient and highly enantioselective process for the preparation of enantiomerically pure cyclopentane-B-amino acids
AU1596299A (en) Method of mobilizing hematopoietic stem cells
AU2260897A (en) Effective production method of be-13793c
AU1039000A (en) Method of sugarcane flower inhibition and new composition